Indexing hint: Review · 2020
Thymosin alpha 1: A comprehensive review of the literature.
Dominari et al. 2020World journal of virologycited by 43
PMID 33362999PMC7747025DOI 10.5501/wjv.v9.i5.67PUB-33362999
Free to read · publisher termsCC BY-NC
Trial · Interventional
RecruitingPhase 2/3Registry dataThymosin-α1 for Recurrent Implantation Failure
Short name Thy-α1 for RIF
NCTNCT07675980 (opens ClinicalTrials.gov in a new tab)Other idFAKIH-2025-13Other idDOH/ADHRTC/2026/345
Overview
- Status
- Recruiting
- Phase
- Phase 2/3
- Enrollment
- 136 participants (estimated)
- Sponsor
- Fakih IVF Fertility Center · Other
- Design
- Randomized · Quadruple masking
- Countries
1 country
United Arab Emirates
- Start
- 11 Feb 2026
- Primary completion
- Feb 2027 (estimated)
- Completion
- Jun 2027 (estimated)
- First posted
- 30 Jun 2026
- Last update posted
- 30 Jun 2026
- Conditions
- Recurrent Implantation Faliure
Timeline
1 trial · 1 ongoing
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
202620272028
- Ph 2/3
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
Interventions
- Thymosin Alpha1Drug
- Placebo ControlOther
Arms2
Experimental
thymosin-α1
Thymosin α1 in recurrent implantation failure patients
Placebo comparator
Placebo
Placebo arm.
Primary outcomes2
Outcomes the sponsor listed as primary.
Live birth more than 24 weeks
Time frame · Approximately 40 weeks
Registry description
From date of randomization (luteal start ART) until end of intervention at 10 + 6 weeks and assessed up to live birth or miscarriage. Approximately 40 weeks.
Determine whether Tα1 increases live birth versus placebo.
Time frame · Approximately 40 weeks
Registry description
Live birth (singleton or multiple)
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
A trial that is still running, or that stopped early, may post results later.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies3
Studies that cite this trial.
Studies with results
1 study on this page
Indexing hint: Animal study · 2007
Thymosin alpha 1: from bench to bedside.
Garaci et al. 2007Annals of the New York Academy of Sciencescited by 33
PMID 17600290DOI 10.1196/annals.1415.044PUB-17600290
Full text at the publisher
PubMed tag: none · 1993
3 results
Low periconceptional maternal serum thymosin alpha 1 levels are associated with blighted pregnancies.
Kaufmann et al. 1993American journal of reproductive immunology (New York, N.Y. : 1989)
PMID 8373526DOI 10.1111/j.1600-0897.1993.tb00583.xPUB-08373526
Full text at the publisher3 results
Eligibility
Who could join, as posted.
- Sex
- Female
- Age
- from 18 Years up to 40 Years
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria:
1. -Women 18-40 years
2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos
3. \- Normal parental karyotypes
4. \- Normal uterine cavity on imaging
5. \- Negative antiphospholipid panel
6. \- Thyroid and prolactin controlled within local reference standards
Exclusion Criteria:
1. Identified/correctable non-immune cause of RPL (chromosomal, anatomic, endocrine)
2. \- Active malignancy
3. -Active infection
4. \- Uncontrolled systemic disease
5. \- Current systemic immunosuppression
PepBank is a research reference. Talk to a doctor before you use any peptide.